FOXD3 and glioblastoma: Functional experiments revealed that FOXD3-AS1 promoted WEE1 expression through sponging miR-128-3p to increase GBM cell survival and TMZ resistance, suggesting that FOXD3-AS1 might be a potential therapeutic target for GBM treatment.